Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022, at 1:40 p.m. ET.

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

The gene-editing specialist's stock is now down roughly 64% over the past 12 months.

Why CRISPR Therapeutics Stock Fell 15.9% Last Month and Continues to Fall

CRISPR Therapeutics AG (CRSP) closed at $62.36 in the latest trading session, marking a +0.76% move from the prior day.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

Shares of Crispr Therapeutics CRSP, +2.79% gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental type 1 diabetes treatment it developed with the privately held ViaCyte Inc. The investigational treatment uses ViaCyte's stem cell-derived therapy in combination with Crispr's gene-editing technology to generate pancreatic cells. Crispr's stock has tumbled 61.0% over the past year, while the S&P 500 SPX, +0.69% has gained 20.4%.

Crispr Therapeutics begins dosing patients in Phase 1 trial for experimental type 1 diabetes treatment

ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D).

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Maravai LifeSciences Holdings

Twist Bioscience Corp

They're risky. But they could also be huge winners.

3 Biotech Stocks That Could Deliver 5X Gains by 2030

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59, marking a +0.41% move from the previous day.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

One of these biotech stocks could have more room to run than the other.

Better Biotech Stock: CRISPR Therapeutics or Twist Bioscience?

It has positive clinical results in hand, a healthy balance sheet, and a strong teammate on its side.

3 Green Flags for CRISPR Therapeutics' Future

Axsome Therapeutics

These two biotechs have potential catalysts to look forward to in 2022.

Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street

CRISPR Therapeutics is a company at the forefront of developing cutting-edge solutions for very difficult to treat diseases.

Crispr Therapeutics: Tons Of Upside From Current Prices

Exelixis

Ionis Pharma

The analysts might be overly optimistic in some cases, though.

3 Biotech Stocks Wall Street Thinks Could Soar 50% or More in 2022

Crispr Therapeutics uses a technology called Crispr-Cas9 to edit genes. Crispr-Cas9 allows gene editing to be cheap, fast, and accurate creating massive potentials for Crispr Therapeutics.

Crispr Therapeutics' Giant Leap For Humankind

The gene-editing stock had a rough run last year, and it's off to a rocky start in 2022.

Why CRISPR Therapeutics Stock Sank 50.5% in 2021 and Continues to Fall

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

The Best CRISPR Companies to Invest In

Ultragenyx Pharmaceutical

Viking Therapeutics

Marinus Pharmaceuticals

Relmada Therapeutics Inc

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022

Both are making progress in a game-changing area.

Better Buy: CRISPR vs. Intellia

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday.

Cathie Wood's ARK Invest Buys Nearly 60,000 Shares of CRISPR

Adaptimmune Therapeutics

Alnylam Pharmaceuticals

Biogen

BioMarin Pharmaceutical

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

4 Biotechs That Could Be Potential Takeover Targets in 2022

SAGE Therapeutics

Novartis

The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on products launched in 2021, or in anticipation of new product announcements.

Top biotech stocks to watch in 2022

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick

Amedisys

Altice USA

Chegg

Frontdoor Inc.

Open Lending Corp

Pan American Silver

Royal Philips

Pinterest

StoneCo

If you're looking for bargain stocks to buy that are down 30% or more in 2021, that's not an easy task. Here are 10 that fit the bill.

10 Bargain Stocks to Buy After Falling 30% in 2021

CRISPR Therapeutics is a gene therapy company pioneering the CRISPR/Cas9 gene editing tool, discovered by its scientific co-founder. The company is partnered with Vertex - a $58bn market cap biotech with >$6bn in cash - on its lead program in Sickle Cell Disease.

Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration

Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.

News for CRISPR Therapeutics Stock (CRSP)